ABBVHealthcare · Drug Manufacturers - GeneralThe 29 Wall Street analysts covering AbbVie, Inc. hold a median 12-month price target of $288 — +0.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 27 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores AbbVie, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Revisions (58): Analysts have, on balance, been cutting their forecasts.
Size (0): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ABBV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +0.7% from it.
Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Oct 2026 | Goldman Sachs | Maintains | Neutral | $258 → $294 |
| 21 Oct 2026 | Barclays | Maintains | Overweight | $300 → $325 |
| 13 Oct 2026 | RBC Capital | Reiterates | Outperform | $280 |
| 13 Oct 2026 | RBC Capital | Reiterates | Outperform | — |
| 9 Oct 2026 | Guggenheim | Reiterates | Buy | $288 |
| 9 Oct 2026 | Guggenheim | Reiterates | Buy | — |
| 9 Oct 2026 | UBS | Maintains | Neutral | — |
| 9 Oct 2026 | UBS | Maintains | Neutral | $260 → $275 |
| 8 Oct 2026 | Cantor Fitzgerald | Maintains | Overweight | $285 → $290 |
| 8 Oct 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 8 Oct 2026 | JP Morgan | Maintains | Overweight | — |
| 8 Oct 2026 | JP Morgan | Maintains | Overweight | $285 → $300 |
| 7 Oct 2026 | Morgan Stanley | Maintains | Overweight | $296 → $310 |
| 7 Oct 2026 | Morgan Stanley | Maintains | Overweight | — |
| 6 Oct 2026 | Scotiabank | Maintains | Sector Outperform | $280 → $320 |
| 6 Oct 2026 | Scotiabank | Maintains | Sector Outperform | — |
| 10 Sept 2026 | HSBC | Maintains | Buy | $300 → $315 |
| 10 Sept 2026 | HSBC | Maintains | Buy | — |
| 20 Aug 2026 | Piper Sandler | Maintains | Overweight | $298 → $303 |
| 20 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ABBV appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, AbbVie, Inc. returned +29.4% against +13.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 9% of US stocks
Cheaper than 16% of US stocks
Cheaper than 99% of US stocks
Cheaper than 17% of US stocks
Higher than 53% of US stocks
Higher than 92% of US stocks
Higher than 87% of US stocks
Higher than 92% of US stocks
Higher than 69% of US stocks
Higher than 11% of US stocks
Higher than 93% of US stocks
Higher than 82% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
AbbVie, Inc. has a market value of $506.1B and an enterprise value of $570.4B.
Revenue in the twelve months to 30 June 2026: $64.4B. The latest quarter grew 10.2% year on year.
Net income over the same four quarters: $6.3B, a 9.8% net margin.
Diluted earnings per share, trailing twelve months: $3.54.
Free cash flow in the twelve months to 30 June 2026: $18.2B.
AbbVie, Inc. spent $1.5B on share buybacks and $12.0B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 81.3×; forward P/E: 17.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.41%, paying out 190% of earnings.
AbbVie, Inc. employs 57,000 people — $1.1M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own AbbVie, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
BOTOX® Cosmetic Day returns on Nov. 18, celebrating personalized treatment across four FDA-approved aesthetic indication areas. The event is described as the biggest offer of the year for Allē Members.
Why it matters — The promotion highlights AbbVie’s BOTOX® Cosmetic offering and its marketing to Allē Members.
The article discusses five high-yield companies across tobacco, pipelines, telecom, pharmaceuticals, and net-lease real estate that have continued raising payouts through recent rate spikes, while noting that Treasury yields near 5% raise the bar for dividend stocks.
Why it matters — AbbVie is in the pharmaceutical sector covered by the article, making its discussion relevant to investors monitoring dividend-paying pharma companies.
Zacks identifies LLY, NVS, JNJ and ABBV as stocks to monitor for arthritis-drug growth potential, citing rising sales, regulatory approvals and clinical advances in inflammatory joint diseases.
Why it matters — ABBV is included among the companies highlighted for potential growth in arthritis drugs.
AbbVie enters Q3 earnings with growth from Skyrizi and Rinvoq, while rising expenses, declining estimates, and intensifying competition create near-term concerns.
Why it matters — ABBV watchers may weigh the drugs’ growth against expense, estimate, and competitive pressures ahead of the earnings report.
A Seeking Alpha article analyzes AbbVie’s performance, pipeline, and pricing ahead of Q3, citing robust 2026 guidance and expected growth from Skyrizi and Rinvoq. It also notes concerns about the aging portfolio and pipeline.
Why it matters — ABBV watchers may find the discussion relevant to assessing the company’s expected near-term performance alongside portfolio and pipeline concerns.
The 29 Wall Street analysts covering AbbVie, Inc. have a median 12-month price target of $288, with estimates ranging from $200 to $325. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 29 analysts covering AbbVie, Inc., 23 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks AbbVie, Inc. 94 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, AbbVie, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 29 analysts implies +0.7% from the last close, and Ticker Nerd's factor model ranks AbbVie, Inc. 94 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering AbbVie, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABBV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $200 to $325 over the next 12 months.
AbbVie, Inc. returned +29.4% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases.
The most recent item we track (PRNewsWire, 28 Oct 2026): "The Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18". BOTOX® Cosmetic Day returns on Nov. 18, celebrating personalized treatment across four FDA-approved aesthetic indication areas. The event is described as the biggest offer of the year for Allē Members.
AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases. AbbVie focuses on major therapeutic areas including immunology, oncology, neuroscience, eye care, aesthetics, and virology, serving patients with chronic autoimmune conditions, blood cancers, inflammatory disorders, and other specialized medical needs. The company’s portfolio includes branded prescription medicines and advanced therapies distributed through physicians, wholesalers, specialty pharmacies, healthcare facilities, and other healthcare channels. AbbVie also supports contract manufacturing services for selected biologics and pharmaceutical processes. Headquartered in North Chicago, Illinois, AbbVie operates as a research-driven healthcare business with a broad international footprint and a strong role in specialty medicine markets.
CEO Mr. Robert A. Michael CPA · 57,000 employees · United States · https://www.abbvie.com
